Mark Jacobstein is the Executive Business Advisor and former CBO for Immunai, a high growth startup using single cell genomics and ML to reprogram the immune system. Mark came to Immunai from Guardant Health, where he spent four years as the CUEO. Prior Mark was CEO of mobile VOIP-pioneer iSkoot until its acquisition by Qualcomm. Mark was also an EVP at loopt (sold to GreenDot) and the co-founding President of Sequoia-backed Digital Chocolate, a pioneer in mobile games. In 1994 Mark founded Small World Sports, the world's first online fantasy sports business, and served as CEO until he sold the business to Paul Allen in 2002. Mark also co-founded Small World Software, which he sold to iXL, where he served as SVP of business development through their 1998 IPO.
The future of drug development is likely to be deeply impacted by machine learning in a multitude of ways. This panel will reflect on the past, present, and future of what has made drug discovery flourish and fail; with a special focus on the technology driving cutting-edge precision medicine.